DENVER, Feb. 21 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that the abstract describing the
effects of darusentan in patients with resistant hypertension was selected for
presentation at ACC.06, the 55th Annual Scientific Session of the American
College of Cardiology, which will be held March 11-14, 2006 at the Georgia
World Congress Center in Atlanta, Georgia.
The abstract highlights the results of a recent trial evaluating the
antihypertensive effect of darusentan in patients with hypertension despite
full (optimized) doses of three antihypertensive medications including a
diuretic, a condition referred to as resistant hypertension. The Phase 2b
dose-ranging trial evaluated darusentan compared to placebo in 115 patients
with resistant hypertension.
Henry Black, M.D., will present "Darusentan Antihypertensive Effect in
Patients with Resistant Hypertension" at the General Hypertension Poster
Session, Presentation Number 915-208, Sunday, March 12, 2006, between
9:00 a.m. and 10:00 a.m. (Eastern). Dr. Black is Professor and Chairman,
Department of Preventive Medicine at Rush University Medical Center and a
principal investigator for the darusentan Phase 2b trial.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently has two product
candidates in late-stage clinical development: ambrisentan for the treatment
of patients with pulmonary arterial hypertension and darusentan for the
treatment of patients with resistant hypertension. The Company also conducts
a target and drug discovery research program focused on the development of
disease-modifying drugs for the treatment of chronic heart failure and related
cardiovascular disorders. Please visit Myogen's website at http://www.myogen.com.
Safe Harbor Statement
This press release contains forward-looking statements that involve
significant risks and uncertainties, including summary statements relating to
the results of the Company's darusentan Phase 2b clinical trial. Actual
results could differ materially from those projected and the Company cautions
investors not to place undue reliance on the forward-looking statements
contained in this release.
Results from and designs of clinical trials, including the Company's
darusentan Phase 2b trial, are not necessarily predictive of future clinical
results or trial designs. Top line results may not be confirmed upon full
analysis of the detailed results of a trial and additional information
relating to the safety, efficacy or tolerability of the Company's product
candidates, including darusentan, may be discovered upon further analysis of
trial data and upon review and analysis of additional trial data, including
data from the Company's anticipated Phase 3 trials of darusentan in resistant
hypertension. If the Company's product candidates do not meet safety or
efficacy endpoints in clinical evaluations, they will not receive regulatory
approval and the Company will not be able to market them. Even if the
Company's product candidates meet safety and efficacy endpoints, regulatory
authorities may not approve them, the Company may not be able to successfully
market them, or the Company may face post-approval problems that require the
withdrawal of its product from the market. The Company's results may be
affected by its effectiveness at managing its financial resources, its ability
to successfully develop and market its product candidates, its ability to
obtain and enforce patent protection for its products, competition from other
biotechnology and pharmaceutical companies, difficulties or delays in
manufacturing its products, and regulatory developments involving current and
future products. Delays in initiating or conducting clinical trials, whether
caused by competition, adverse events, patient enrollment rates, regulatory
issues or other factors, could adversely affect the Company's financial
position and prospects. If the Company is unable to raise additional capital
when required or on acceptable terms, it may have to significantly delay,
scale back or discontinue one or more of its drug development or discovery
research programs. Myogen is at an early stage of development and may not
ever have any products that generate significant revenue.
Additional risks and uncertainties relating to the Company and its
business can be found in the "Risk Factors" section of Myogen's Form 10-K for
the year ended December 31, 2004 and Myogen's reports on Form 10-Q and Form
8-K. It is Myogen's policy to only update or reconfirm its public guidance by
issuing a press release or filing a periodic or current report with the
Securities and Exchange Commission. All information in this press release is
as of February 21, 2006. Myogen undertakes no duty or obligation to update
any forward-looking statements contained in this release as a result of new
information, future events or changes in the Company's expectations.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
